Upfront rational therapy in BRAF V600E mutated pediatric ameloblastoma promotes ad integrum mandibular regeneration.
BRAF inhibitor therapy
ameloblastoma targeted therapy
regenerative therapy
Journal
Journal of tissue engineering and regenerative medicine
ISSN: 1932-7005
Titre abrégé: J Tissue Eng Regen Med
Pays: England
ID NLM: 101308490
Informations de publication
Date de publication:
12 2021
12 2021
Historique:
revised:
22
09
2021
received:
25
02
2021
accepted:
25
09
2021
pubmed:
3
10
2021
medline:
22
3
2022
entrez:
2
10
2021
Statut:
ppublish
Résumé
Ameloblastoma is a neoplasm arising in the craniofacial skeleton. Proliferating odontogenic epithelial cells comprise this benign, yet locally invasive tumor, often causing severe disfiguration. High recurrence rate entails ablative surgical resection, which is the current standard of care, resulting in subsequent critical size osteocutaneous defects. The high incidence of BRAF mutations in ameloblastoma, most notably the BRAF V600E mutation, enabled the use of BRAF inhibiting agent in a neoadjuvant setting. In this investigator-initiated, open-label study, three consecutive pediatric patients, with confirmed BRAF V600E ameloblastoma deemed marginally resectable, were treated with BRAF inhibiting agents, prior to undergoing surgery. The use of upfront BRAF inhibitor treatment resulted in substantial tumor regression, allowing for non-mutilating complete surgical removal, ad integrum bone regeneration and organ preservation. All patients showed a marked radiologic and clinical response to medical treatment, enabling successful conservative surgery. Microscopically, all patients showed evidence of minimal residual tumor with extensive tumor necrosis, fibrosis and generation of new bone. At a median follow-up of 31 months, all patients remained free of disease. Face preservation therapy was achieved in pediatric patients presenting with BRAF V600E mutated ameloblastoma. Our study demonstrates the translational potential of targeted therapy as a neoadjuvant agent. Patient-specific organ preservation therapy should be considered as the new standard of care in ameloblastoma, mainly for children and adolescents.
Substances chimiques
BRAF protein, human
EC 2.7.11.1
Proto-Oncogene Proteins B-raf
EC 2.7.11.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1155-1161Informations de copyright
© 2021 John Wiley & Sons Ltd.
Références
Abrahams, J. M., & McClure, S. A. (2016). Pediatric odontogenic tumors. Oral and Maxillofacial Surgery Clinics of North America, 28, 45-58. https://doi.org/10.1016/j.coms.2015.08.003
Borrelli, M. R., Hu, M. S., Longaker, M. T., & Lorenz, H. P. (2020). Tissue engineering and regenerative medicine in craniofacial reconstruction and facial aesthetics. Journal of Craniofacial Surgery, 31, 15-27. https://doi.org/10.1097/SCS.0000000000005840
Brown, N. A., Rolland, D., McHugh, J. B., Weigelin, H. C., Zhao, L., Lim, M. S., Elenitoba-Johnson, K. S. J., & Betz, B. L. (2014). Activating FGFR2-RAS-BRAF mutations in ameloblastoma. Clinical Cancer Research, 20, 5517-5526. https://doi.org/10.1158/1078-0432.CCR-14-1069
Chong, H. S., Tsujigiwa, H., Ishak, I., Hussin, N. M., Nagatsuka, H., & Ng, K. H. (2015). RANK, RANKL, and OPG in recurrent solid/multicystic ameloblastoma: Their distribution patterns and biologic significance. Oral Surgery Oral Medicine Oral Pathology Oral Radiology, 119, 83-91. https://doi.org/10.1016/j.oooo.2014.09.017
Doumas, S., Foukas, P. G., Economopoulou, P., Kotsantis, I., & Psyrri, A. (2020). Atypical patterns of responses in the era of immune checkpoint inhibitors in head and neck cancer. Oral Oncology, 100, 104477. https://doi.org/10.1016/j.oraloncology.2019.104477
Effiom, O. A., Ogundana, O. M., Akinshipo, A. O., & Akintoye, S. O. (2018). Ameloblastoma: Current etiopathological concepts and management. Oral Diseases, 24, 307-316. https://doi.org/10.1111/odi.12646
El-Naggar, A. K. (2017). World Health Organization classification of head and neck tumours (4th ed.). IARC Press.
Faden, D. L., & Algazi, A. (2016). Durable treatment of ameloblastoma with single agent BRAF; Clinical and radiographic response with combined BRAF-targeted therapy in stage 4 ameloblastoma. Journal of National Cancer Institute, 26, 109-110. https://doi.org/10.1093/jnci/djw190
Fernandes, G. S., Girardi, D. M., Bernardes, J. P. G., Fonseca, F. P., & Fregnani, E. R. (2018). Clinical benefit and radiological response with BRAF inhibitor in a patient with recurrent ameloblastoma harboring V600E mutation. BMC Cancer, 18, 887-892. https://doi.org/10.1186/s12885-018-4802-y
Fowler, N. M., & Futran, N. D. (2014). Utilization of free tissue transfer for pediatric oromandibular reconstruction. Facial Plastic Surgery Clinics of North America, 22, 549-557. https://doi.org/10.1016/j.fsc.2014.07.001
Hirschhorn, A. I., Vered, M., Buchner, A., Greenberg, G., & Yahalom, R. (2013). Unicystic ameloblastoma in an infant: A management dilemma. Craniomaxillofacial Surgery, 41, 226-e230. https://doi.org/10.1016/j.jcms.2013.01.023
Hupp, J. (2019). Contemporary oral and maxillofacial surgery (7th ed.). Elsevier.
Ma, N., Teng, X., Zheng, Q., & Chen, P. (2019). The regulatory mechanism of p38/MAPK in the chondrogenic differentiation from bone marrow mesenchymal stem cells. Journal of Orthopaedic Surgery and Research, 14, 434-442. https://doi.org/10.1186/s13018-019-1505-2
McClary, A. C., West, R. B., McClary, A. C., Pollack, J. R., Fischbein, N. J., Holsinger, C. F., Sunwoo, J., Colevas, A. D., & Sirjani, D. (2016). Ameloblastoma: A clinical review and trends in management. European Archives of Oto-Rhino-Laryngology, 273, 1649-1661. https://doi.org/10.1007/s00405-015-3631-8
Mendenhall, W. M., Werning, J. W., Fernandes, R., Malyapa, R. S., & Mendenhall, N. P. (2007). Ameloblastoma. American Journal of Clinical Oncology, 30, 645-648. https://doi.org/10.1097/COC.0b013e3181573e59
Pajarinen, J., Lin, T., Gibon, E., Kohno, Y., Maruyama, M., Nathan, K., Lu, L., Yao, Z., & Goodman, S. B. (2019). Mesenchymal stem cell-macrophage crosstalk and bone healing. Biomaterials, 196, 80-89. https://doi.org/10.1016/j.biomaterials.2017.12.025
Rifkin, W. J., Kantar, R. S., Ali-Khan, S., Plana, N. M., Diaz-Siso, J. R., Tsakiris, M., & Rodiriguez, E. D. (2018). Facial disfigurement and identity: A review of the literature and implications for facial transplantation. American Medical Association Journal of Ethics, 20, 309-323. https://doi.org/10.1001/journalofethics.2018.20.4.peer1-1804
Shirsat, P. M., Bansal, S., Prasad, P., & Desai, R. S. (2018). Low frequency of BRAF V600E immunoexpression in mandibular ameloblastomas: An institutional study. Journal of Oral and Maxillofacial Pathology, 22, 353-359. https://doi.org/10.4103/jomfp.JOMFP_174_17
Sweeney, R. T., McClary, A. C., Mywers, B. R., Biscocho, J., Neahring, L., Kwei, K. A., Qu, K., Gong, X., Ng, T., Jones, C. D., Varma, S., Odegaard, J. I., Sugiyama, T., Koyota, S., Rubin, B. P., Troxell, M. G., Pelham, R. J., Zehnder, J. L., Beachy, P. A., … West, R. B. (2014). Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nature Genetics, 46, 722-725. https://doi.org/10.1038/ng.2986
Tan, S., Pollack, J. R., Kaplan, M. J., Colevas, A. D., & West, R. B. (2016). BRAF inhibitor treatment of primary BRAF-mutant ameloblastoma with pathologic assessment of response. Oral Surgery Oral Medicine Oral Pathology Oral Radiology, 122, e5-e7. https://doi.org/10.1016/j.oooo.2015.12.016
Thouverey, C., & Caverzasio, J. (2015). Focus on the p38 MAPK signaling pathway in bone development and maintenance. BoneKEy Reports, 4, 4. https://doi.org/10.1038/bonekey.2015.80
Zippel, D., Markel, G., Shapira-Frommer, R., Ben-Betzalel, G., Goitein, D., Ben-Ami, E., Nissan, A., Schacter, J., & Scneebaum, S. (2017). Perioperative BRAF inhibitors in locally advanced stage III melanoma. Journal of Surgical Oncology, 116, 856-861. https://doi.org/10.1002/jso.24744